Novo Nordisk A/S (NYSE:NVO) Shares Sold by ICW Investment Advisors LLC

ICW Investment Advisors LLC reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 2.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 41,497 shares of the company’s stock after selling 843 shares during the period. Novo Nordisk A/S accounts for about 2.7% of ICW Investment Advisors LLC’s portfolio, making the stock its 2nd largest holding. ICW Investment Advisors LLC’s holdings in Novo Nordisk A/S were worth $5,923,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its holdings in Novo Nordisk A/S by 38.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 94,544 shares of the company’s stock worth $9,781,000 after buying an additional 26,067 shares during the last quarter. McKinley Carter Wealth Services Inc. increased its stake in shares of Novo Nordisk A/S by 37.0% during the 4th quarter. McKinley Carter Wealth Services Inc. now owns 60,356 shares of the company’s stock worth $6,244,000 after purchasing an additional 16,293 shares during the last quarter. Bank of New Hampshire raised its holdings in shares of Novo Nordisk A/S by 1,356.8% in the 1st quarter. Bank of New Hampshire now owns 13,257 shares of the company’s stock valued at $1,702,000 after purchasing an additional 12,347 shares during the period. Cim LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at about $23,547,000. Finally, Burford Brothers Inc. bought a new position in Novo Nordisk A/S during the fourth quarter worth about $1,045,000. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on NVO shares. BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Argus raised their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a report on Monday, June 10th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Monday, August 19th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Monday, August 19th. Finally, The Goldman Sachs Group began coverage on shares of Novo Nordisk A/S in a report on Thursday, May 30th. They set a “buy” rating and a $156.00 target price for the company. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $145.17.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock traded up $2.04 during trading on Friday, reaching $132.93. The company’s stock had a trading volume of 223,897 shares, compared to its average volume of 4,309,018. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. The business’s 50-day moving average price is $135.03 and its 200-day moving average price is $132.42. Novo Nordisk A/S has a 52 week low of $86.96 and a 52 week high of $148.15. The firm has a market cap of $596.53 billion, a PE ratio of 45.13, a P/E/G ratio of 1.52 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The business had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Equities analysts forecast that Novo Nordisk A/S will post 3.11 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were paid a dividend of $0.5126 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 24.83%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.